Celmed acquires NeuroGeneration and NeuroGenomics
Theratechnologies' newly created subsidiary, Celmed BioSciences (cell therapy), has acquired two California-based companies developing therapeutics for neurodegenerative diseases, NeuroGeneration and NeuroGenomics, for $12mm in Celmed shares.
- Full Acquisition
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com